On Developing Non-invasive Cervical Precancer Treatments - Women's Health Series with Alia Rahman

Twenty-First Century Treatments for Women's Health.

In the second episode of Narratives of Purpose's special series on Advancing Women's Health, host Claire Murigande speaks with Alia Rahman, the Co-founder and CEO of Amplexd Therapeutics.

Alia shares her personal journey with dysplasia, how it motivated her to establish Amplexd, and the company's mission of developing treatments to improve patient experience and accessibility for HPV-induced cervical dysplasia.

Alia raises awareness of the healthcare system's failings towards women's health, particularly in the treatments of cervical precancer. She highlights the focus on unique treatment strategies, such as non-invasive and low-cost options.

Be sure to visit our podcast website for the full episode transcript.

References for content mentioned in this episode:

• CIN classifications summary by the Cleveland Clinic
• "ASC-US" term explanation
• Gender bias in medicine article
• Gender funding gap data by UBS

RELEVANT LINKS:

• More about Amplexd Therapeutics at this website
• Follow Amplexd: LinkedIn
• Connect with our guest, Alia Rahman: LINKEDIN

• Read our Women's Health articles: blog posts
• Follow our host: WEBSITE | LINKEDIN
• Follow us: LinkedIn | Instagram
• Connect with us: narrativespodcast@gmail.com | subscribe to our news
• Tell us what you think: write a review

This special series on Advancing Women's Health with Female Founders is supported by TechFace, Lean In Switzerland, and Ladies Drive.

CHAPTERS:

0:00 Episode Introduction

00:40 Introducing Amplexd Therapeutics

01:54 Introducing the Host and the Podcast

02:45 Alia's Journey with Amplexd

06:23 Understanding Cervical Intraepithelial Neoplasia

08:01 Alia's Personal Experience and the Origin of Amplexd

12:37 Amplexd's Mission

13:22 The Role of AI and Technology in Healthcare

15:59 The Future of Women-led Innovation in Healthcare

19:09 The Importance of Funding Women-led Startups

20:25 Closing Remarks and Further Resources